Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr 12;11(4):1509-26.
doi: 10.3390/ijms11041509.

Oxidative stress, molecular inflammation and sarcopenia

Affiliations
Review

Oxidative stress, molecular inflammation and sarcopenia

Si-Jin Meng et al. Int J Mol Sci. .

Abstract

Sarcopenia is the decline of muscle mass and strength with age. Evidence suggests that oxidative stress and molecular inflammation play important roles in age-related muscle atrophy. The two factors may interfere with the balance between protein synthesis and breakdown, cause mitochondrial dysfunction, and induce apoptosis. The purpose of this review is to discuss some of the major signaling pathways that are activated or inactivated during the oxidative stress and molecular inflammation seen in aged skeletal muscle. Combined interventions that may be required to reverse sarcopenia, such as exercise, caloric restriction, and nutrition, will also be discussed.

Keywords: chronic inflammation; interventions; oxidative stress; sarcopenia; signaling.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A schematic summary of proposed mechanisms by which oxidative stress and chronic inflammation could contribute to sarcopenia. Some major signaling pathways are activated or inactivated during the oxidative stress and chronic inflammation seen in aged skeletal muscle. The pathways are related to an imbalance of protein synthesis and breakdown, mitochondrial dysfunction, and apoptosis, leading to fiber atrophy and fiber loss, eventually to sarcopenia.
Figure 2.
Figure 2.
Hypothetical scheme for how combined interventions can affect sarcopenia.

References

    1. Rosenberg IH. Sarcopenia: Origins and clinical relevance. J. Nutr. 1997;127:990S–991S. - PubMed
    1. Faulkner JA, Larkin LM, Claflin DR, Brooks SV. Age-related changes in the structure and function of skeletal muscles. Clin. Exp. Pharmacol. Physiol. 2007;34:1091–1096. - PubMed
    1. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J. Am. Geriatr. Soc. 2004;52:80–85. - PubMed
    1. Daw CK, Starnes JW, White TP. Muscle atrophy and hypoplasia with aging: Impact of training and food restriction. J. Appl. Physiol. 1988;64:2428–2432. - PubMed
    1. Lexell J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J. Neurol. Sci. 1988;84:275–294. - PubMed

Substances

LinkOut - more resources